Adaptive Biotechnologies Corp — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Adaptive Biotechnologies reported Q2 2026 revenue of $71.6M (22% YoY growth), with MRD segment revenue at $66.2M (+33% YoY) representing 92% of total revenue. The company completed a $345M zero-coupon convertible senior notes offering, repaid the OrbiMed Purchase Agreement (eliminating a $131.2M liability), and raised full-year 2026 MRD revenue guidance to $268M–$278M (26–31% growth). Management announced plans to separate MRD and Immune Medicine businesses. Cash position strengthened to $371.7M as of June 30, 2026 (from $70.5M at year-end 2025). Net loss of $39.9M in Q2 (including $23.7M loss on revenue interest liability extinguishment; adjusted net loss $16.2M) reflects continued GAAP losses, though MRD segment achieved positive Adjusted EBITDA of $9.1M.
Why this rating
Meaningful capital raise ($345M) and liability elimination significantly improve balance sheet. MRD growth (33% YoY) and raised guidance reflect strong commercial traction. Business separation is strategically material. However, company still cash-flow negative; relative to ~$1.4B market cap, the financing and guidance improvements are substantial but execution risks remain on separation.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.